Compare Ascendis Pharma A/S (ASND) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Marqeta Inc — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Marqeta Inc trades at $16.78 (market cap $1.67B). The key difference: Ascendis Pharma A/S is far larger — about 10.6× Marqeta Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MQ | |
|---|---|---|
Market Cap | $17.74B | $1.67B |
Sector | Health | Technology |
52-Week High | $277.18 | $27.32 |
52-Week Low | $163.32 | $15.04 |
Enterprise Value | $18.11B | $972.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MQ trades at $15.87, up 2.32% today, with a bearish technical signal and neutral oscillators. Revenue has improved from $507M in 2024 to $625M in 2025, though net income remains negative. The company recently announced a 4:1 reverse stock split effective July 1, 2026, and will report Q2 2026 earnings on August 4, 2026. Analyst consensus is a buy rating with a $19.00 price target, indicating potential upside from current levels.
MQ shows revenue growth and expanding European presence, but profitability is weak with a high P/E of 396.75. Risks include ongoing net losses, competitive fintech pressures, and shareholder litigation. The stock offers speculative growth potential if execution improves, but investors face significant fundamental and sentiment headwinds near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
